港股異動|再鼎醫藥放量升逾16% Q1產品收入淨額同比增39%
再鼎醫藥(9688.HK)大幅上升超16%,現報15.22港元,成交額放大至1.28億港元,總市值151億港元。該公司一季度產品收入淨額合計為8710萬美元,同比增長39%;按固定匯率(CER)計算同比增長43%;研發開支為5460萬美元,同比增加12.58%;截至2024年3月31日現金儲備為7.508億美元。公司創始人、董事長兼首席執行官杜瑩博士表示,展望未來,我們預計將在今年接下來的時間加速商業化工作,為2024年三個新的潛在產品上市做好準備。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.